BioCentury | Apr 20, 2018
Company News

Mylan gets worldwide rights to glatiramer acetate depot

...Mapi-Pharma Ltd., Ness Ziona, Israel Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Neurology Alicia Parker Glatiramer acetate Depot (ga depot) Mapi-Pharma Ltd. Mylan...
BioCentury | Apr 7, 2017
Finance

Taking notice

...TPEx-E:6521) (D) 3/9/16 TBD Mkt (tools & services) Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Jan 6, 2017
Finance

Good riddance

...TBD Ph II AnaptysBio Inc. 9/9/15 TBD Preclin Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...Inc. (NYSE) 8/26/15 Up to $1B Mkt (device) Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Jul 11, 2016
Finance

Ground up

...N.V. (NYSE) 6/8/15 Up to $100M Mkt (services) Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Apr 4, 2016
Finance

Fundamental reset

...U.A. (NYSE) 6/8/15 Up to $100M Mkt (services) Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Feb 1, 2016
Financial News

Mapi-Pharma amends IPO

...million Shares: 3.1 million Price: $15-$17 Underwriters: JMP Securities; Maxim Group; FBR Overallotment: 468,750 Note: Mapi-Pharma...
...In May 2014, Mapi-Pharma proposed to sell 2.7 million shares at $13-$15. In March 2014, Mapi-Pharma...
BioCentury | Jan 4, 2016
Finance

Curbed enthusiasm

...Mkt (services) Anterios Inc. 3/31/15 $50.7M Ph II Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Oct 26, 2015
Financial News

Mapi-Pharma amends IPO

...To be raised: TBD Shares: TBD Price: TBD Underwriters: JMP Securities; Maxim Group; FBR Note: Mapi-Pharma...
...raised. The company also removed MLV as an underwriter and added FBR. In May 2014, Mapi-Pharma...
...company proposed to sell 2.9 million shares at the same price range. In March 2014, Mapi-Pharma...
BioCentury | Oct 5, 2015
Finance

Volatile, not futile

...Ph II Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Silenseed Ltd. 6/13/14 TBD Ph I/II Mapi-Pharma Ltd....
Items per page:
1 - 10 of 24
BioCentury | Apr 20, 2018
Company News

Mylan gets worldwide rights to glatiramer acetate depot

...Mapi-Pharma Ltd., Ness Ziona, Israel Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Neurology Alicia Parker Glatiramer acetate Depot (ga depot) Mapi-Pharma Ltd. Mylan...
BioCentury | Apr 7, 2017
Finance

Taking notice

...TPEx-E:6521) (D) 3/9/16 TBD Mkt (tools & services) Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Jan 6, 2017
Finance

Good riddance

...TBD Ph II AnaptysBio Inc. 9/9/15 TBD Preclin Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...Inc. (NYSE) 8/26/15 Up to $1B Mkt (device) Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Jul 11, 2016
Finance

Ground up

...N.V. (NYSE) 6/8/15 Up to $100M Mkt (services) Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Apr 4, 2016
Finance

Fundamental reset

...U.A. (NYSE) 6/8/15 Up to $100M Mkt (services) Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Feb 1, 2016
Financial News

Mapi-Pharma amends IPO

...million Shares: 3.1 million Price: $15-$17 Underwriters: JMP Securities; Maxim Group; FBR Overallotment: 468,750 Note: Mapi-Pharma...
...In May 2014, Mapi-Pharma proposed to sell 2.7 million shares at $13-$15. In March 2014, Mapi-Pharma...
BioCentury | Jan 4, 2016
Finance

Curbed enthusiasm

...Mkt (services) Anterios Inc. 3/31/15 $50.7M Ph II Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Mapi-Pharma Ltd....
BioCentury | Oct 26, 2015
Financial News

Mapi-Pharma amends IPO

...To be raised: TBD Shares: TBD Price: TBD Underwriters: JMP Securities; Maxim Group; FBR Note: Mapi-Pharma...
...raised. The company also removed MLV as an underwriter and added FBR. In May 2014, Mapi-Pharma...
...company proposed to sell 2.9 million shares at the same price range. In March 2014, Mapi-Pharma...
BioCentury | Oct 5, 2015
Finance

Volatile, not futile

...Ph II Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Silenseed Ltd. 6/13/14 TBD Ph I/II Mapi-Pharma Ltd....
Items per page:
1 - 10 of 24